Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
1.000
+0.030 (3.08%)
At close: Jan 3, 2025, 4:00 PM
0.950
-0.050 (-5.00%)
After-hours: Jan 3, 2025, 4:09 PM EST
Kronos Bio Employees
As of December 31, 2023, Kronos Bio had 63 total employees, including 62 full-time and 1 part-time employees. The number of employees decreased by 34 or -35.05% compared to the previous year.
Employees
63
Change (1Y)
-34
Growth (1Y)
-35.05%
Revenue / Employee
$156,571
Profits / Employee
-$1,358,508
Market Cap
60.34M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63 | -34 | -35.05% |
Dec 31, 2022 | 97 | 1 | 1.04% |
Dec 31, 2021 | 96 | 33 | 52.38% |
Dec 31, 2020 | 63 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
KRON News
- 5 weeks ago - Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewsWire
- 7 weeks ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 2 months ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 3 months ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 3 months ago - Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - GlobeNewsWire
- 3 months ago - Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - GlobeNewsWire
- 3 months ago - Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - GlobeNewsWire
- 4 months ago - Kronos Bio Announces Participation in Medical and Investor Conferences in September - GlobeNewsWire